Navigation Links
Patient Enrollment in Urgent(R) PC SUmiT Clinical Trial Completed Ahead of Schedule
Date:1/26/2009

kets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent PC system, which we believe is the only FDA-approved minimally invasive nerve stimulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence - symptoms often associated with overactive bladder.

We also offer Macroplastique(R) Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

Forward Looking Information

This press release contains forward-looking statements, which reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may effect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC. Further, we cannot assure you that the SUmiT clinical trial will produce favorable results, that even if it produces favorable results third-party payers will provide or continue to provide coverage and reimbursement, or reimburse the providers an amount sufficient to cover their costs and expenses, or that even succeed at all at obtaining a specific "listed" CPT code from the AMA for Urgent PC treatments.

For more information about the Urgent(R) PC Neuromodulation System, please call 866-277-0466 or visit www.uroplasty.com.

For Further Information:

    Uroplasty, Inc.                               EVC Group
    David Ka
'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... commitments from institutional investors to purchase an aggregate of ... an at-the-market registered direct offering, led by a dedicated ... definitive purchase agreements with these investors pursuant to which ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
(Date:1/15/2014)... Fla. , Jan. 15, 2014  In an unprecedented effort to ... TB in ambulances and other transport vehicles, an advanced and portable ... rescue personnel for the first time. In order ... with these deadly pathogens, West Palm Beach ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2
... VIEJO, Calif., Oct. 12, 2011 Avanir Pharmaceuticals, Inc. ... affect (PBA) prevalence data from stroke survivors will be ... Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine in ... details about the data presentation at ACRM/ASNR Progress ...
... Good Start Genetics,™ Inc., an innovative molecular diagnostics ... screening, today announced that it will present results ... next-generation DNA sequencing platform at the Annual Meeting ...  ASRM will be held from October 15-19, 2011 ...
Cached Medicine Technology:Avanir Pharmaceuticals to Present Data at the 2011 American Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine Annual Conference 2Good Start Genetics to Announce Validation Study Results for its Next-Generation DNA Sequencing Platform During an Oral Presentation at the 2011 Annual Meeting of the American Society for Reproductive Medicine (ASRM) 2
(Date:4/23/2014)... Center researchers say clinical trials for a new ... are very promising. Patients treated with CPX-351, a ... are showing better responses than patients treated with ... "Acute myeloid leukemia is an aggressive blood cancer ... in older patients," explained Jeffrey Lancet, M.D., senior ...
(Date:4/23/2014)... to high-energy particles, simulating conditions astronauts would face on ... and slower reaction times, even when the radiation exposure ... impairments which affected a large subset, but far ... linked to protein changes in the brain, the scientists ... humans, suggest it may be possible to develop a ...
(Date:4/23/2014)... falls below normal levels are more likely to have ... disease and type 2 diabetes. A new simple screening ... and possible treatment is described in an article in ... from Mary Ann Liebert, Inc., publishers. The article is ... website at http://www.liebertpub.com/jmh . , ...
(Date:4/23/2014)... often displayed in the popular Swedish children,s TV ... high-sugar foods. A new study from the University ... children,s TV programmes as well as the link ... weight status. , Steingerdur Olafsdottir,s doctoral thesis focuses ... Swedish children,s TV show Bolibompa. Healthy foods dominated ...
(Date:4/23/2014)... of Midlife Occupational and Leisure Time Physical Activity on ... activity in midlife increases the risk of mobility limitation ... risk. This is found in a study which followed ... study was conducted at the Gerontology Research Center in ... Heavy physical labor is often repetitive, wears the body ...
Breaking Medicine News(10 mins):Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2
... half their concerns, so doctors should listen carefully, ... -- Older patients and surgeons don,t communicate effectively ... decision to have surgery can be particularly difficult ... School of Medicine study. , The researchers recorded ...
... Air-Pulse Autonomic Meditation Therapy is a non-denominational therapy that allows ... identity many feel when adopting ancient mind controlling meditative healings. ... ... 14, 2008 –- Dr. Ajrawat,s http://www.painmanagement.com/ [Air-Pulse Autonomic ...
... childhood asthma, but, when compared to girls, they are also ... have a decreased incidence of asthma in the post-pubertal years. ... asthma development, according to a prospective study that analyzed airway ... moderate asthma over a period of about nine years. , ...
... the past two decades, medication errors have dramatically increased. DecisionHealth, ... potentially harmful medication errors. , ... Gaithersburg, MD (PRWEB) ... Health Ledger,s recent drug overdose, increased dramatically over the past two ...
... Investigators from the Melbourne Center of the international Ludwig Institute ... reported that they have developed a test to predict whether ... metastatic Stage IV cancer and death. , More than ... has spread to the lymph nodes will typically have ...
... Investment to Close in September, Subject to Stockholder ... Potential Launch of MOXATAG(TM), GERMANTOWN, Md., Aug. ... a pharmaceutical company focused on,developing and commercializing novel ... the quarter ended June 30,2008., MiddleBrook reported ...
Cached Medicine News:Health News:Older Adults Reluctant to Question Surgical Treatment 2Health News:Dr. Ajrawat's Air-Pulse Autonomic Meditation Therapy, a Revolutionary, Scientific, Meditation Therapy, Receives Patent Trademark 2Health News:Dr. Ajrawat's Air-Pulse Autonomic Meditation Therapy, a Revolutionary, Scientific, Meditation Therapy, Receives Patent Trademark 3Health News:Dr. Ajrawat's Air-Pulse Autonomic Meditation Therapy, a Revolutionary, Scientific, Meditation Therapy, Receives Patent Trademark 4Health News:Dr. Ajrawat's Air-Pulse Autonomic Meditation Therapy, a Revolutionary, Scientific, Meditation Therapy, Receives Patent Trademark 5Health News:Asthma in boys may be just a phase, but for girls it may be there to stay 2Health News:Fatalities From Medication Errors at Home Up Dramatically - DecisionHealth Offers Solutions 2Health News:Fatalities From Medication Errors at Home Up Dramatically - DecisionHealth Offers Solutions 3Health News:Prototype test for predicting clinical outcome for melanoma patients 2Health News:Prototype test for predicting clinical outcome for melanoma patients 3Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 2Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 3Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 4Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 5Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 6Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 7Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 8Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 9Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 10Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 11Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 12Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 13
Infusion Cannula, 2.0mm....
Subretinal Fluid Cannula, Curved; 20g (0.90) x 1-1/2" (38mm); 12mm Flexible Tubing Extends 6mm Beyond Tip; Curved at 65°....
Micro Vitreoretinal Cannula; Angled; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 65°, 1mm from Tip....
...
Medicine Products: